Buscar
Mostrando ítems 1-8 de 8
Artículo
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
| Fecha del documento:
2021 | Derechos de autor:
open access
Artículo
Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation
| Fecha del documento:
2023 | Derechos de autor:
open access
Artículo
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production
| Fecha del documento:
2020 | Derechos de autor:
open access
Artículo
Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts
| Fecha del documento:
2022 | Derechos de autor:
open access
Artículo
Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
| Fecha del documento:
2017 | Derechos de autor:
open access
Artículo
Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication
| Fecha del documento:
2019 | Derechos de autor:
open access
Artículo
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
| Fecha del documento:
2019 | Derechos de autor:
open access
Artículo
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators
| Fecha del documento:
2020 | Derechos de autor:
open access